Frequently Asked Questions - HemoTech™ FAQ
- 1. What is HemoBioTech, Inc.’s core product?
- HemoBioTech, Inc.’s core product is HemoTech™, potentially the first viable substitute for human blood addressing the broad blood use market.
- 2. What is HemoTech™?
- HemoTech™ is a novel blood substitute that is based on hemoglobin (which is a key protein in red blood cells that carries oxygen) capable of replacing the oxygen carrying and volume of red blood cells in the human body.
- 3. What makes HemoTech™ a novel blood substitute?
- HemoTech™ is comprised of hemoglobin that has been isolated from bovine blood and then chemically modified with adenosine, ATP and GSH to make the product non-toxic.
- 4. Who invented HemoTech™?
- HemoTech™ was invented with persistent efforts by two of the leading world-renowned blood substitute scientists, Dr. Jan Simoni and Dr. Mario Feola from Texas Tech University Health Sciences Center at Lubbock, Texas.
- 5. Are there additional features of HemoTech™?
- Yes, other than replacing the oxygen carrying and volume properties of red blood cells, HemoTech™
- • Induces erythropoiesis (red blood cell production)
- • Has anti-inflammatory activity
- 6. Can HemoTech™ be used with different blood types?
- Yes, HemoTech™ is compatible with all blood types.
- 7. What are the significant properties of HemoTech™?
- Based on studies to date, HemoTech™ is:
- • Non-toxic
- • Anti-inflammatory
- • Vasodilatory
- • Antigenically pure and free of infections
- 8. What is the shelf life of HemoTech™?
- HemoTech™ has a shelf life of 6+ months at 4° C versus 42 days of conventional blood. HemoTech™ can be stockpiled and transported.
- 9. What is the composition of HemoTech™?
- HemoTech™ combines pure bovine hemoglobin with o-adenosine 5’- triphosphate (o-ATP), o-adenosine and reduced glutathione (GSH). Inter and intra–molecular cross linkers eliminate toxicity and impart pharmacological activity.
- 10. How does HemoTech™ reduce toxicity?
- Bovine hemoglobin undergoes polymerization and the hemoglobin is chemically modified as in 9. above, to reduce or eliminate toxicity.
- 11. Has HemoTech™ undergone any clinical testing?
- HemoTech™ entered limited foreign human clinical testing, which indicated the compound’s biological activity and non-toxicity in humans. The clinical trial was performed at the Institute de la Recherché en Sciences de la Sante, Centre dé l Anemie S.S in Zaire.
- 12. What did the test involve?
- The clinical trial involved nine sickle cell anemia patients injected with significant amounts of HemoTech™ representing 25% of total blood volume.
- 13. What did the results indicate?
- The results indicated no toxicity and significant patient improvement and overall improvement in their general condition and induction of erythropoiesis, although there is no guarantee that additional testing will give the same results.
- 14. Has HemoTech™ undergone any clinical testing in the U.S.A?
- No. Currently, HemoBioTech, Inc. is preparing to file an Investigational New Drug (IND) application for HemoTech™ with the FDA in order to start clinical trials in the U.S.A.
- 15. Is HemoTech™ patented?
- Yes, HemoTech™ is patented in 21 global markets in Europe, Asia, and North America.
- 16. What is the Company’s relationship with Texas Tech University
Health
Sciences Center at Lubbock, Texas?
- • HemoBioTech, Inc.’s relationship with Texas Tech University Health Sciences Center is governed by a Sponsored Research Agreement (“SRA”) and a License Agreement.
- • HemoBioTech, Inc. has an exclusive worldwide license from Texas Tech University System covering all Intellectual property (IP) associated with HemoTech™.
- • Services of Dr. Jan Simoni, one of the world’s leading experts in the field of blood substitutes.